Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Abroad (travel likely)RecruitingPHASE2

Conditions

Autosomal Dominant Polycystic Kidney · Obesity

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
Contact: Study coordinator (Kristen Nowak, PhD, MPH) · Kristen.Nowak@cuanschutz.edu · 303-724-4842
Contact: Principal Investigator (Kristen Nowak, PhD, MPH)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Abroad (travel likely)RecruitingPHASE2

Garden Grove, United States · Huntington Park, United States

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

Abroad (travel likely)RecruitingPHASE2

Zurich, Switzerland · Chur, Switzerland

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

Abroad (travel likely)RecruitingPHASE1

Birmingham, United States · Loma Linda, United States

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Abroad (travel likely)RecruitingPHASE2

Alabaster, United States · Birmingham, United States